美国食品和药物管理局授予阿布图斯的乙型肝炎药物imdusiran快速追踪地位. FDA grants Fast Track status to Arbutus' hepatitis B drug imdusiran.

美国食品和药物管理局已为其用于治疗慢性乙型肝炎的实验药物imdusiran授予快速指标. Arbutus Biopharma宣布,该公司将在2019年3月份发布的一项新研究报告中指出: Arbutus Biopharma announced that the U.S. FDA has granted Fast Track designation to its experimental drug imdusiran for treating chronic hepatitis B. 这种状态旨在加快治疗的开发和审查,其目的是实现功能性治愈. This status is intended to expedite the development and review of the therapy, which aims to achieve a functional cure. 通过向病毒的RNA水平,Imdusiran起作用. 在临床试验中,它减少了病毒蛋白和抗原,这表明有前景. Imdusiran works by targeting the virus at the RNA level and has shown promise in clinical trials by reducing viral proteins and antigens.